Login to Your Account

APE-ing success of VEGF? Phase I launch by Apexian may portend cancer wins

By Randy Osborne
Staff Writer

Wednesday, January 24, 2018

The FDA cleared Apexian Pharmaceuticals Inc.'s IND for oncology candidate APX-3330 in three days, CEO Steve Carchedi told BioWorld, "which is probably a world record. It was, at that time, the most widely used unapproved drug," with safety data in no fewer than 422 patients already available.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription